Novel coronavirus – SARS CoV-2

1. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis. 2005;24:223-7.10.1097/01.inf.0000188166.17324.60Search in Google Scholar

2. Zhong N, Zheng BY, Li Y, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong. People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353-8.10.1016/S0140-6736(03)14630-2Search in Google Scholar

3. Wang N, Shi L, Zhang S, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986-90.10.1038/cr.2013.92Search in Google Scholar

4. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.10.1016/S0140-6736(20)30251-8Search in Google Scholar

5. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6:e1001005.10.1371/journal.ppat.1001005290854820661479Search in Google Scholar

6. Shereen A, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Advanc Res. 2020;24:91-8.10.1016/j.jare.2020.03.005711361032257431Search in Google Scholar

7. Ashour H, Elkhatib W, Rahman M, et al. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020;9:186.10.3390/pathogens9030186715763032143502Search in Google Scholar

8. Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529-57.10.1146/annurev-micro-020518-11575931226023Search in Google Scholar

9. Lin X, Gong Z, Xiao Z, et al. Novel coronavirus pneumonia outbreak in 2019: Computed tomographic findings in two cases. Korean J Radiol. 2020;21(3):365-8.10.3348/kjr.2020.0078703971432056397Search in Google Scholar

10. Velavan TP, Meyer C. The Covid-19 epidemic. Tropical Med Int Health 2020;25(3):278-80.10.1111/tmi.13383716977032052514Search in Google Scholar

11. Zhu, N, Zhang D, Wang, et al. Investigating, China Novel Coronavirus, 2019. Research Team. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382(8):727-33.10.1056/NEJMoa2001017709280331978945Search in Google Scholar

12. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl Med. 2020; 382:1708-20.10.1056/NEJMoa2002032709281932109013Search in Google Scholar

13. Definicja przypadku na potrzeby nadzoru nad zakażeniami ludzi nowym koronawirusem SARS-CoV-2. GIS; www.gis.gov.pl.Search in Google Scholar

14. Phan T. Novel coronavirus: from discovery to clinical diagnostics. Infect. Genet Evol. 2020;79;104211.10.1016/j.meegid.2020.104211712979932007627Search in Google Scholar

15. Nishiura H, Linton NM, Akhmetzhanov AR. Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission. J Clin Med. 2020;9(2):488.10.3390/jcm9020488707372432054045Search in Google Scholar

16. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22(2):74-9.10.1016/j.micinf.2020.01.003710255632017984Search in Google Scholar

17. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020;9(1):747-56.10.1080/22221751.2020.1745095717270132196430Search in Google Scholar

18. Guangdi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149-50.10.1038/d41573-020-00016-032127666Search in Google Scholar

19. Wu C, Liu Y, Yang, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. APSB. 2020;10(5):766-88.10.1016/j.apsb.2020.02.008710255032292689Search in Google Scholar

20. Wang, M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.10.1038/s41422-020-0282-0705440832020029Search in Google Scholar

21. Solidarity clinical trial for COVID-19 treatments. WHO, www.who.intSearch in Google Scholar

22. Amant F, Krammer F, SARS CoV-2 Vaccines: Status Report. Immunity 2020; doi: 10.1016/j.immuni.2020.03.007 [Epub ahead of print].10.1016/j.immuni.2020.03.007713686732259480Search in Google Scholar

23. Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.10.1016/j.meegid.2020.104260710620332092483Search in Google Scholar

24. Morais IJ Jr, Polveiro RC, Souza GM, et al. The global population of SARS-CoV-2 is composed of six major subtypes. bioRxiv. https://doi.org/10.1101/ 2020.04.14.040782.10.1038/s41598-020-74050-8758842133106569Search in Google Scholar

25. Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:179,10.1186/s12967-020-02344-6717492232321524Search in Google Scholar

• Gut microbiome in non-alcoholic fatty liver disease

• SARS-CoV-2 antibody screening in healthcare workers: lessons learned from the first months of COVID-19 outbreak in Europe. Significance of serology testing for effective pandemic management and reduction of the occupational risk